BWS Financial Upgrades SciClone Pharmaceuticals (SCLN) to Buy, Risk Removed
Tweet Send to a Friend
BWS Financial upgraded SciClone Pharmaceuticals (NASDAQ: SCLN) from Hold to Buy with a price target of $8.25 after a regulatory ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
